Fairchem Organics (FAIRCHEMOR) Q2 FY27 Profit Soars 1220% as Margins Rebound
Fairchem Organics posted a massive 1220% jump in quarterly profit, driven by a sharp rebound in operating margins as import pressure eased.
Fairchem Organics' Q2 FY27 profit surged to ₹10.17 crore, up 1220% year-on-year. The leap was powered by a 540 basis point expansion in net profit margin, even as revenue dipped slightly from the prior quarter.
Fairchem Organics’ second quarter tells a story of recovery from a deep trough. A year ago, the specialty oleochemicals maker was grappling with weak demand and aggressive Chinese imports that crushed its profitability. This quarter, profit surged more than twelvefold, signaling a sharp operational rebound even as sales volume softened.
The headline numbers show the scale of the turnaround. Revenue for the quarter ended September 2026 stood at ₹166.92 crore, up 49.7% from a depressed base a year ago. The real story is the bottom line: profit after tax leapt to ₹10.17 crore from just ₹0.77 crore in Q2 FY26. This translated to a net profit margin of 6.1%, a dramatic 540 basis point improvement.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 166.92YoY +50% | 176.15 | 111.52 |
| Profit (₹ Cr) | 10.17YoY +1221% | 10.01 | 0.77 |
| Net Profit Margin (%) | 6.1YoY +771% | 5.7 | 0.7 |
Why Margins Expanded Sharply
The massive profit jump was driven by a strong operating leverage effect. According to reports from scanx.trade, EBITDA for the first half of FY27 improved to 10.32%, driven by better realizations in the domestic market. Management had cited reduced dumping pressure from China and an ability to pass through higher raw material costs during the Q1 call, a trend that appears to have held.
Sequentially, revenue dipped 5.2% from the June quarter's ₹176.15 crore. Yet profit still inched up 1.6%, meaning the entire gain came from fatter margins, not more sales. A report from Stockwatch.live notes this quarter missed management's own guidance for 5-7% sequential volume growth, highlighting that the recovery remains price-led rather than volume-driven.
The Outlook and Lingering Risks
Management remains cautiously optimistic. The company is targeting a rise in capacity utilization from around 60% to 70-75% by FY27-end, as noted in prior concall highlights. A new 40,000 MT oleochemical plant was slated for commissioning this quarter, which could support future volume growth. The company also reduced its current borrowings by ₹15 crore in the first half, strengthening its balance sheet.
Live Chart
· FAIRCHEMOR
(BSE)
ISIN: INE0DNW01011
However, the recovery is fragile. The primary risk, as management has acknowledged, is the return of low-priced Chinese imports. An inverted duty structure—where raw materials attract a higher tariff than finished products—also creates a persistent margin headwind. The progress of high-margin products like Isostearic Acid, which currently contributes just 4% of sales, will be key to building a more durable profitability profile.
Key Points
- Fairchem Organics' Q2 FY27 profit surged 1220% year-on-year to ₹10.17 crore, driven by a 540 basis point expansion in net profit margin.
- The margin improvement was supported by better domestic realizations as import pressure from China eased, allowing cost pass-through.
- Sequentially, revenue declined 5.2% while profit edged up, indicating the profit growth was entirely margin-led and missed volume growth targets.
- The company is focusing on ramping up capacity utilization and a new product plant, but faces risks from a potential return of Chinese dumping and an inverted duty structure.
- Strengthening its financial position, the company reduced its current borrowings by ₹15.13 crore in the first half of FY27.
Hexa Perspective
Fairchem’s quarter is a clear rebound from an exceptionally weak period, but it leaves the durability of the gains open. The profit surge is impressive, yet it springs from a margin recovery on stable—not growing—sequential sales. For the momentum to hold, the company needs its new capacity and products to translate into consistent volume growth.
The path forward hinges on two external factors: the absence of renewed Chinese price competition and the successful commercialization of its specialty products. Until then, the earnings profile may remain susceptible to the same pricing pressures that caused the prior downturn. Investors are paying a slight premium for this recovery, with the stock's P/E of 38.2 just above the industry average of 36.9.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.